Artificial Intelligence Machine Learning CyberSecurity Robotics Blockchain
The FDA cleared Bayer’s Sunharbo (asundexian), the first Factor XIa inhibitor, after a 12,327-patient trial showed a 26% drop in repeat ischemic strokes without more major bleeding. Here is what the approval means for Bayer, its rivals and payers.
The FDA cleared Bayer’s Sunharbo (asundexian), the first Factor XIa inhibitor, after a 12,327-patient trial showed a 26% drop in repeat ischemic strokes without more major bleeding. Here is what the approval means for Bayer, its rivals and payers.
Vanderbilt told students to shut down devices after BYOD ransomware hit its network and threats played from campus computers. The same gang claims it stole Medicaid, SNAP and banking records on about two million Texans from the state’s health agency. Here’s what’s confirmed, what isn’t, and what businesses should do.
The FDA cleared Bayer’s Sunharbo (asundexian), the first Factor XIa inhibitor, after a 12,327-patient trial showed a 26% drop in repeat ischemic strokes without more major bleeding. Here is what the approval means for Bayer, its rivals and payers.
Read more
For decades, the health community has preached a simple sleep gospel: get eight hours, and you will be fine. But
Read more
A board probe sent Nvidia shares down 4.3% on Monday and cut Jensen Huang’s net worth by about $6.5 billion, dropping him to 12th on the Bloomberg Billionaires Index. With roughly 98% of his fortune in one stock, his week is a textbook case of concentration and key-person risk for founders and business owners.
Read more
